ANP32A was shown to inhibit cell transformation15, 16, 17 and has reduced expression in prostate and breast cancer.18, 19ANP32E was reported to have enhanced expression in gastric cancer,20 and a high expression of ANP32E was associated with better survival rate in follicular lymphoma.21 Previously we reported that ANP32B, also designated as PHAPI2 or SSP29, is a negative prognostic indicator for human breast cancer.22 Full analysis of the expression and functional role of ANP32B in cancer progression has still not been undertaken. This evidence concerns the gene ANP32B and follicular lymphoma.